AUTHORS
Cristina Giubbilei, MD, Alessio Mazzoni2, Sara Pratesi3, Ginevra Giustini4, Agnese Baffioni5, Valentina Carrai6
AFFILIATIONS
1 Hematology Unit, AOU Careggi, Florence, Italy
2 Dipartimento Medicina sperimentale e clinica, University of Florence, Florence, Italy
3 SOD Diagnostica Citofluorimetrica e Immunologica AOU Careggi, Florence, Italy
4 Hematology Unit, AOU Careggi, Florence, Italy
5 Hematology Unit, AOU Careggi, Florence, Italy
6 Hematology Unit, AOU Careggi, Florence, Italy
ABSTRACT
BackgroundThe pathogenesis of primary immune thrombocytopenia (ITP) is complex and not completely understood. Historically attributed to a Bcell–driven autoreactive milieu, it has recently been reframed within the context of autoreactive B–Tcell interactions that impair platelet production and clearance. Among candidate immunomarkers, CD21^low B cells and circulating T-follicular helper (Tfh) cells may indicate chronic activation and support autoantibody formation. We aimed to characterize peripheral blood CD21^low and Tfh in treatment-naïve patients with ITP and to assess their relationship with platelet count, compared with healthy controls and patients with non-immune thrombocytopenia.
MethodsWe conducted an observational study of 28 treatment-naïve adults with primary ITP, 14 healthy controls (HC) and 7 disease controls (DC; hereditary non-autoimmune thrombocytopenia). Peripheral blood was collected at basaline before ITP-directed treatment.Flow cytometry with standardized gating quantified B and T-cell. Pairwaise comparison among cohorts were performed using two-sided mann-whitney U tests. Associations between CD21^low or Tfh frequencies and plt count were assessed by two-sided spearman rank correlation in the combined ITP+HC population. A p-value <0.05 was considered significant.
ResultsAmong ITP patients, 16/28 (57.1%) were women; median age at diagnosis was 51.5 years [38.3–66.0]. Eighteen patients (64.3%) had chronic ITP, including acute-on-chronic disease, 2 (7.1%) persistent ITP, and 8 (28.6%) newly diagnosed ITP. Median disease duration was 3.11 years [0.06–5.53]. Median platelet counts were 53.5×10?/L [27.3–76.8] at diagnosis and 44.0×10?/L [21.3–63.5] at sampling. Bleeding manifestations according to WHO-Bleeding Scale were present in 5/28 patients (17.9%). 13 patients (46.4%) received first-line treatment after sampling; among them, 8/13 (61.5%) achieved complete response, 3/13 (23.1%) partial response, and 2/13 (15.4%) no response. As expected, platelet counts were markedly higher in HC than in both ITP and DC (265.0 [233.5–308.5] vs 44.0 [21.3–63.5] and 23.0 [21.0–64.0] ×10?/L, respectively; both p<0.001), whereas no significant difference was observed between ITP and DC (p=0.967). CD21^low frequencies were significantly higher in ITP than in HC: 8.35% [5.60–12.75] vs 4.90% [4.13–5.93] (p=0.008). DC showed intermediate values, 5.10% [3.65–7.80] (p=0.04). Tfh frequencies were numerically higher in ITP than in HC, 11.60% [8.05–16.23] vs 8.45% [7.58–9.55], but the difference did not reach statistical significance (p=0.0547).DC showed a median Tfh frequency of 9.00% [8.20–15.10], with no significant difference versus ITP (p=0.9507) or HC (p=0.3703).In the combined ITP+HC population (n=42), CD21^low frequency showed inverse correlation with platelet count (Spearman ρ=−0.405, p=0.0078), whereas the correlation between Tfh and platelet count wasn’t significant (ρ=−0.251, p=0.108)
Conclusion In treatment-naive ITP, CD21low were significantly expanded vs HC and inversely correlated with platelet count, supporting a role for chronic B-cell activation in disease pathophysiology. Tfh cells showed a concordant but non-significant trend, likely reflecting limited statistical power rather than a true absence of effect. These findings put CD21low on evidence as a intriguing biomarker of disease in ITP, while Tfh requires further validation. Larger cohorts are needed to clarify whether CD21low/Tfh reflect an ITP-specific feature.
DISCLOSURES
Cristina Giubbilei, MD: No relevant conflicts of interest to declare.